Our current data are in line with our prior in vivo findings, providing the effectiveness of simultaneous co-administration of BAY 11-7082 [24], in suppressing Stat3 and Egfr expression, both important contributors to HNSCC pathogenesis [13, 30], further emphasizing the need to develop a therapeutic strategy for targeting NF-κB in head and neck malignancies. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.